FDA-approved ADCs have drastically changed clinical practices for the treatment of urothelial cancer (Powles et al., 2021), HER2-positive breast cancer (Hurvitz et al., 2023) and CD30-positive peripheral T-cell lymphoma (Horwitz et al., 2022) and other cancer types (Figure 2). This evidence concerns the gene ERBB2 and breast cancer.